The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the services, contract terms, and products they offer. Across this competitive industry is a common mission
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the Congressional Budget Office’s (CBO) $43 billion score of point-of-sale rebates in Medicare Part D. CBO’s score is the latest in a series of official estimates
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the Administration’s new Blueprint on drug pricing: “We share the Administration’s goal of reducing drug prices. The key is to increase competition among drug companies so
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting tactic that will only result in increased prescription drug costs in a recent op-ed published
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following remarks by Food and Drug Administration Commissioner Scott Gottlieb: “Manufacturers have chosen to negotiate price concessions with pharmacy benefit managers (PBMs) using rebates, which are
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
Even including discounts, however, the company’s net profit margin for 2017 was 34 percent, its highest since at least 2000, when it was half that high.
High spending on prescription drugs with both orphan and non-orphan indications suggest potential misuse of Orphan Drug Act designations.
So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug costs for consumers — if enacted, “delinking” would hand a financial windfall totaling up to
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug costs for consumers — if enacted, “delinking” would hand a
©2024 PCMA. All Rights Reserved.
